|
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. |
|
|
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Lilly (Inst); Pfizer (Inst); Roche (Inst) |
Research Funding - AstraZeneca (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Lilly; Pfizer; Roche |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly/ImClone; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech |
Research Funding - Puma Biotechnology; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Travel, Accommodations, Expenses - Lilly |
|
|
No Relationships to Disclose |
|
Clarisse Audigier-Valette |
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche; Sysmex |
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Roche; Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly/ImClone; Novartis; Pfizer; Roche/Genentech; Sanofi |
Travel, Accommodations, Expenses - Lilly/ImClone; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Roche Pharma AG |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Roche Pharma AG |
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Pfizer; Roche Pharma AG |
Travel, Accommodations, Expenses - Lilly; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |